Recent studies have shown that the presence of tumor-residing stem cell–like T cells is predictive of response (Peng et al., 2021; Rong et al., 2022; Sade-Feldman et al., 2018), suggesting the potential of stem cell–like CD4 T cells as a pan-cancer predictive biomarker for treatment response. The gene discussed is CD4; the disease is cancer.